Q1 FY2027 · ended Jun 30, 2026 · Revenue $1.48M, +504.9% YoY · Filed Aug 14, 2026
Vistagen Therapeutics, Inc. (VTGN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q1 of fiscal 2027, the quarter ended Jun 30, 2026, it reported revenue of $1.5 million and a net loss of $13.0 million. As of Jun 30, 2026 it held $31.7 million in cash and investments and $783,000 in total debt.
Revenue
$1.48M
+504.9% vs year-ago quarter
Net income
$-13.03M
+13.7% vs year-ago quarter
Operating cash flow
$-14.71M
+22.0% vs year-ago quarter
Free cash flow
—
EPS
$-0.30
+36.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
44.38M
+44.6% vs year-ago quarter
Net cash
$30.95M
Q1 FY2027
Operating margin
-2785.7%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTGN (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1411685
- Former names
- Excaliber Enterprises, Ltd. (until Jun 8, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jun 30, 2026 |
Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
Q1 FY2026 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $465,000 | $303,000 | $258,000 | $244,000 |
| Operating income | -$13.3M | -$16.7M | -$19.5M | -$20.1M | -$15.8M |
| Net income | -$13.0M | -$16.3M | -$18.9M | -$19.4M | -$15.1M |
| Diluted EPS | -$0.30 | -$0.38 | -$0.45 | -$0.54 | -$0.47 |
| Operating cash flow | -$14.7M | -$16.2M | -$17.6M | -$13.8M | -$18.8M |
| Total assets | $35.7M | $48.6M | $65.1M | $80.9M | $68.9M |
| Total liabilities | $11.3M | $13.0M | $14.1M | $14.6M | $12.2M |
| Stockholders' equity | $24.5M | $35.5M | $50.9M | $66.3M | $56.8M |
| Cash and investments | $31.7M | $45.4M | $61.8M | $77.2M | $63.2M |
| Total debt | $783,000 | $948,000 | $1.0M | $1.2M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Exit or restructuring costs, Other events
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 25, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 11, 2026 | Sep 10, 2026 |
All 908 Vistagen Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.